Pharma BD Deal Intelligence

Abbott Laboratories / Solvay Pharmaceuticals

2010 · Acquisition/Merger · $6.2B · Complete

Abbott completed acquisition of Solvay's pharmaceuticals unit for $6.2B (€4.5B), expanding emerging markets and pharmaceutical product portfolio. Deal originally announced 2009, closed February 2010.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 15yr post-close.

Key facts

Announced Feb 08, 2010
Closed Feb 15, 2010
Deal value $6.2B
Deal type Acquisition/Merger
Therapeutic area Cardiometabolic, gastroenterology, vaccines
Indications Cardiometabolic, gastroenterology, vaccines
Key assets AndroGel; Creon; Influvac vaccine portfolio
Mechanism Mixed pharmaceutical portfolio

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals